A wrap-up of the biggest health policy news of 2019
To close out a busy year, MM&M rounded up the biggest health policy developments of 2019.
Legal/Regulatory
Open enrollment on pace amid ACA uncertainty
The healthcare law is facing court challenges, but enrollment is chugging on.
J&J lays out defense strategy for Ohio opioid trial. It feels familiar
Trial briefs filed yesterday by drug makers and other defendants revealed arguments to be used in the upcoming trial.
Juul suspends product advertising as new CEO steps in
K.C. Crosthwaite is replacing Kevin Burns as CEO.
Oklahoma judge orders Johnson & Johnson to pay $572m in landmark opioid trial
The judge ruled that J&J’s marketing of painkillers contributed to the state’s opioid crisis.
Senate Finance Committee draws up comprehensive drug price bill
“This legislation shows that no industry is above accountability,” said Senators Chuck Grassley and Ron Wyden.
Novartis looks to settle doc-bribery suit; CEO shares update on Zolgensma coverage
The Swiss drugmaker, which reported an otherwise upbeat second quarter, allocated a substantial reserve to settle bribery charges stemming from the suit.
J&J’s legal troubles mount
The company’s failed bid to have the Oklahoma opioid case tossed was followed this week by a reported criminal probe into its talcum baby powder.
Another Trump drug price proposal bites the dust
A proposal to end rebates negotiated by PBMs was pulled back by the White House on Thursday. It’s the second drug price idea to be scrapped this week.
Judge: HHS overstepped bounds issuing list price disclosure rule
The rule requiring drugmakers to state the price of treatments in DTC ads was set to go into effect on Tuesday.
